Sunday, November 15, 2026

Peer-Reviewed Clinical Evidence Platform

The research that matters, without the jargon.

Peer-reviewed breakthroughs in plain English alongside verified outcomes, evidence grades, and clinical study details for everyone from everyday readers to medical students.

ClearMed Editorial Digest500 briefings across 12 specialties121 Phase III & clinical practice

Indexed from PubMed, NEJM, The Lancet, JAMA, Nature MedicineSaved Library

Health Hubs:

Stage: Evidence:

Showing 6 briefings matching “inflammation”

Reset all filters

Oncology

Oncology Clinical Briefings

Peer-Reviewed Clinical Digests · Verified Scientific Media

ONCOLOGY · CLINICAL PRACTICE

Decades-Old Mystery Solved: New Anti-Inflammatory Defense Found

A newly identified immune defense mechanism protects healthy cells from inflammation, opening new avenues for treating inflammatory diseases and cancer. This breakthrough offers a novel target for therapeutic interventions in a range of inflammatory conditions.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readScienceDailyNov 12, 2026

ONCOLOGY · CLINICAL PRACTICE

Gut Bacterium's Toxin Directly Triggers Colon Cancer

A toxin produced by *Bacteroides fragilis* directly damages the colon and fuels inflammation, acting as a key driver in colorectal cancer development. This breakthrough provides a crucial missing link in our understanding of how gut microbiota can influence cancer development.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readScienceDailyNov 12, 2026

ONCOLOGY · CLINICAL PRACTICE

Gut Bacterium's Toxin Directly Drives Colon Cancer

The toxin produced by the common gut bacterium *Bacteroides fragilis* directly damages the colon and drives colorectal cancer development through inflammation. This discovery resolves a long-standing mystery regarding the link between gut bacteria and colorectal cancer, providing crucial mechanistic insight.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readScienceDailyNov 12, 2026

ONCOLOGY · REAL-WORLD COHORT

Blood-based RNA biomarker for the early detection of ovarian cancer

Prospective evaluation in consecutively enrolled real-world cohorts is required to validate diagnostic performance, predictive value and clinical utility. Tu-stroma showed no systematic elevation across inflammatory or physiologic comparators (n = 116) or nonovarian malignancies (n = 160), each assessed against healthy controls (n = 100), supporting disease-context specificity.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readNature MedicineNov 10, 2026

ONCOLOGY · REAL-WORLD COHORT

Determinants of response to CAR T cell therapy in a multicenter, multi-trial cohort analysis of patients with lymphoma

The evidence generated by this study has the potential to advance the development of more effective cellular therapies. An inverse correlation was observed between prior lines of therapy and the proportion of naive-like T cells in both product and matched apheresis samples, suggesting a benefit of earlier intervention.

4/5 Strong Trial

Evidence Meter · 4/5

Strong Clinical Evidence

Tested directly in patients through a prospective clinical trial or large multicenter human cohort.

1 min readNature MedicineOct 23, 2026

ONCOLOGY · PHASE I/II

EGFR-targeted antibody-toxin conjugate in recurrent glioma: a phase 1 trial

These findings indicate that EGFR-targeted D2C7-ATC therapy prolongs survival in a subset of patients with IDHwt rGBM via intratumoral and systemic immune activation. . Eight patients died on trial; all deaths were unrelated to D2C7-ATC.

4/5 Strong Trial

Evidence Meter · 4/5

Strong Clinical Evidence

Tested directly in patients through a prospective clinical trial or large multicenter human cohort.

1 min readNature MedicineOct 16, 2026

Interactive Fact Check